Elutia Q4 2024: BioEnvelope sales +18% to $2.7M; EluPro pilot launch gains traction; net loss $9.1M

ELUTIA INC.

Q4 BioEnvelope sales $2.7M (+18% YoY); overall net sales $5.5M (-7% YoY) due to SimpliDerm and cardiovascular declines.
EluPro accounted for over 30% of BioEnvelope sales in Q4; 67 approved accounts and ~100 actively ordering.
Q4 GAAP gross margin improved to 42.5% (from 36.2%); adjusted gross margin 58.1% (from 50.6%).
Full year 2024 net loss from continuing ops $54.1M vs $41.2M; adjusted EBITDA loss narrowed to $12.9M from $14.4M.
Year-end cash $13.2M; raised ~$15M gross proceeds in February 2025 registered direct offering.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.